Top Research Reports for Verizon, The Southern Co. & Blackstone
Research Reports Overview: Zacks Research Daily features reports on 16 major stocks, including Verizon, Southern Company, and Blackstone, highlighting their performance, market challenges, and growth prospects, particularly in sectors like wireless technology and clean energy.
Market Insights: The "Ahead of Wall Street" article provides investors with insights into economic releases affecting market actions, while the ongoing tariff saga impacts pre-market trading negatively.
Trade with 70% Backtested Accuracy
Analyst Views on UTMD
About UTMD
About the author
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Earnings Report Overview: Utah Medical Products, Inc. (UTMD) reported a 4% decline in earnings per share and a 4.3% decrease in net sales for Q2 2025 compared to the previous year, with domestic sales slightly increasing while international sales dropped significantly.
Future Outlook: Management anticipates continued weakness in PendoTECH sales affecting full-year results, but remains optimistic about achieving a trailing twelve-month EBITDA target of $16 million to $18 million despite current challenges.
Daily Dividend Report: WELL,PFG,CTVA,UTMD,ENB,WFC
Dividend Increases Announced: Several companies, including Principal Financial Group, Corteva, Utah Medical Products, Enbridge, and Wells Fargo, have announced increases in their quarterly dividends for 2025, reflecting a commitment to returning capital to shareholders.
Upcoming Dividend Payment Dates: The declared dividends will be payable on various dates in September and October 2025, with specific record dates for shareholders noted for each company.
Top Analyst Reports for JPMorgan, Novartis & AT&T
Research Reports on Major Stocks: The Zacks Research Daily highlights new reports on 16 significant stocks, including JPMorgan Chase, Novartis, and AT&T, along with insights into micro-cap companies like Perma-Pipe International and Utah Medical Products, emphasizing unique research on smaller firms.
Market Trends and Company Performance: Key findings indicate that JPMorgan is expected to see net interest income growth despite fee income challenges, Novartis benefits from a strong drug portfolio amid competition, and AT&T continues to thrive in the wireless sector while facing challenges in its wireline division.
Validea Benjamin Graham Strategy Daily Upgrade Report - 6/18/2025
Validea's Value Investor Model: The model, based on Benjamin Graham's strategy, has upgraded Utah Medical Products Inc (UTMD) from a 71% to an 86% rating due to improved fundamentals and valuation, indicating strong interest in the stock.
Company Overview: Utah Medical Products, Inc. specializes in developing medical devices for women's healthcare and critical care, offering a variety of products including those for postpartum hemorrhage control and neonatal care.
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Earnings Report Overview: Utah Medical Products, Inc. (UTMD) reported a 4% decline in earnings per share and a 4.3% decrease in net sales for Q2 2025 compared to the previous year, with domestic sales slightly increasing while international sales dropped significantly.
Future Outlook: Management anticipates continued weakness in PendoTECH sales affecting full-year results, but remains optimistic about achieving a trailing twelve-month EBITDA target of $16 million to $18 million despite current challenges.
Daily Dividend Report: WELL,PFG,CTVA,UTMD,ENB,WFC
Dividend Increases Announced: Several companies, including Principal Financial Group, Corteva, Utah Medical Products, Enbridge, and Wells Fargo, have announced increases in their quarterly dividends for 2025, reflecting a commitment to returning capital to shareholders.
Upcoming Dividend Payment Dates: The declared dividends will be payable on various dates in September and October 2025, with specific record dates for shareholders noted for each company.
Top Analyst Reports for JPMorgan, Novartis & AT&T
Research Reports on Major Stocks: The Zacks Research Daily highlights new reports on 16 significant stocks, including JPMorgan Chase, Novartis, and AT&T, along with insights into micro-cap companies like Perma-Pipe International and Utah Medical Products, emphasizing unique research on smaller firms.
Market Trends and Company Performance: Key findings indicate that JPMorgan is expected to see net interest income growth despite fee income challenges, Novartis benefits from a strong drug portfolio amid competition, and AT&T continues to thrive in the wireless sector while facing challenges in its wireline division.
Validea Benjamin Graham Strategy Daily Upgrade Report - 6/18/2025
Validea's Value Investor Model: The model, based on Benjamin Graham's strategy, has upgraded Utah Medical Products Inc (UTMD) from a 71% to an 86% rating due to improved fundamentals and valuation, indicating strong interest in the stock.
Company Overview: Utah Medical Products, Inc. specializes in developing medical devices for women's healthcare and critical care, offering a variety of products including those for postpartum hemorrhage control and neonatal care.
